2-[3-[(6-methyl-3-pyridyl)oxy]phenyl]-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone | 1552296-62-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[3-[(6-methyl-3-pyridyl)oxy]phenyl]-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone
• 英文别名: 2-[3-(6-Methylpyridin-3-yl)oxyphenyl]-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone；2-[3-(6-methylpyridin-3-yl)oxyphenyl]-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone
• CAS: 1552296-62-4
• 化学式: C₂₃H₂₁F₃N₄O₂
• 分子量: 442.441
• InChiKey: WJQXUKQOWMYKLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-氯-6-三氟甲基烟酸 在 manganese(IV) oxide 、 硼烷四氢呋喃络合物 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 53.0h， 生成 2-[3-[(6-methyl-3-pyridyl)oxy]phenyl]-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone
  参考文献：
  名称：

  Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach

  摘要：

  Novel compounds based on the lead BRS-3 agonists from our HTS compounds 2a and 2b have been synthesized with the focus on obtaining peripheral BRS-3 agonists. To identify potent anti-obesity compounds without adverse effects on the central nerve system, a labile carboxylic ester with an antedrug functionality was introduced onto the terminal position. Through the extensive synthetic exploration and the pharmacokinetic studies of oral administration in mice, the phenol ester 17c was selected due to the most suitable pharmacological profile. In the evaluation of food intake suppression in B6 mice, 17c showed significant in vivo efficacy and no clear adverse effect on heart rate and blood pressure change in dog iv infusion. Our study paved the way for development of anti-diabetes and obesity drugs with a safer profile. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.018

文献信息

• Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration
  作者：Tetsuyoshi Matsufuji、Kousei Shimada、Shozo Kobayashi、Asuka Kawamura、Teppei Fujimoto、Tsuyoshi Arita、Takashi Hara、Masahiro Konishi、Rie Abe-Ohya、Masanori Izumi、Yoshitaka Sogawa、Youko Nagai、Kazuhiro Yoshida、Hisashi Takahashi

  DOI：10.1016/j.bmcl.2013.12.106

  日期：2014.2

  The discovery and optimization of a novel series of BRS-3 agonists are described. We explored a potent BRS-3 agonist with low brain penetration to avoid an adverse effect derived from central nervous system exposure. Through the derivatization process, chiral diazepines 9f and 9g were identified as possessing low brain penetration as well as potent in vitro activity against human and mouse BRS-3s. (C) 2014 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach
  作者：Tetsuyoshi Matsufuji、Kousei Shimada、Shozo Kobayashi、Masanori Ichikawa、Asuka Kawamura、Teppei Fujimoto、Tsuyoshi Arita、Takashi Hara、Masahiro Konishi、Rie Abe-Ohya、Masanori Izumi、Yoshitaka Sogawa、Yoko Nagai、Kazuhiro Yoshida、Yasuyuki Abe、Takako Kimura、Hisashi Takahashi

  DOI：10.1016/j.bmc.2014.11.018

  日期：2015.1

  Novel compounds based on the lead BRS-3 agonists from our HTS compounds 2a and 2b have been synthesized with the focus on obtaining peripheral BRS-3 agonists. To identify potent anti-obesity compounds without adverse effects on the central nerve system, a labile carboxylic ester with an antedrug functionality was introduced onto the terminal position. Through the extensive synthetic exploration and the pharmacokinetic studies of oral administration in mice, the phenol ester 17c was selected due to the most suitable pharmacological profile. In the evaluation of food intake suppression in B6 mice, 17c showed significant in vivo efficacy and no clear adverse effect on heart rate and blood pressure change in dog iv infusion. Our study paved the way for development of anti-diabetes and obesity drugs with a safer profile. (C) 2014 Elsevier Ltd. All rights reserved.